Project Grant R01HL179052
Award Date 8/25/26
Completion Date 5/31/31
Dollars Obligated $656K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $354,982 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms driving lung fibrosis following severe viral respiratory infections. The research dissects how aberrant immune-epithelial interactions perpetuate post-viral lung damage distinct from idiopathic pulmonary fibrosis. The work focuses on three objectives: defining mechanisms that sustain...
- The National Heart, Lung, and Blood Institute awarded Emory University $391,211 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 1, 2026, to investigate alloimmune responses and anti-drug antibody formation against coagulation factor therapeutics in hemophilia patients. The research addresses inhibitor development—the formation of neutralizing antibodies against Factor VIII and Factor IX replacement therapies—which complicates treatment in approximately 30 percent of...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $117,552 on January 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lymphatic endothelial alpha globin in heart failure progression. The research examines how alpha globin expression in lymphatic endothelial cells mediates cardiac remodeling and chronic inflammation in cardiometabolic heart failure. Using genetically modified mice with inducible alpha globin...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $234,750 project grant effective August 1, 2025, through July 31, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports basic immunological research investigating anti-Factor VIII (FVIII) Immunoglobulin M (IgM) responses in hemophilia A patients. The research aims to identify immunologic mechanisms that initiate and orchestrate the formation...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $444,125 to the University of Virginia on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode immune responses during sequential rhinovirus infections. The recipient will conduct a comprehensive analysis of immune cells and anti-viral mediators in blood and nasal specimens collected during sequential homotypic and heterotypic...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $718,991 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to determine the role of red blood cells in sepsis heterogeneity. The funded research investigates how red blood cells capture and deliver cell-free bacterial DNA to immune cells and distant organs during sepsis, a dysregulated host response to infection that remains a leading cause of death. The project...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...